FDA Approves Outlook Therapeutics Eye Disease Drug
The FDA approved Outlook Therapeutics' Lytenava for treating wet age-related macular degeneration. This marks the company's first U.S. commercial entry following a successful regulatory appeal. The drug is expected to launch by the end of the year with twelve years of market exclusivity.
X24 PerspectiveRelated Assets:
X24 Perspective